Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
Shinji Kobuchi, Yukako Ito, Taro Hayakawa, Asako Nishimura, Nobuhito Shibata, Kanji Takada, Toshiyuki Sakaeda
Index: Xenobiotica 45(1) , 19-28, (2014)
Full Text: HTML
Abstract
1. The aim of this study was to develop a simple pharmacokinetic-pharmacodynamic (PK-PD) model that could characterize the complete time-course of alterations in platelet counts to predict the onset and degree of thrombocytopenia, which severely limits the use of the anticancer agent 5-fluorouracil (5-FU), in rats. 2. Platelet counts were measured in rats following the intravenous administration of various doses of 5-FU for 4 days to obtain data for an analysis of the PK-PD model. Our PK-PD model consisted of a two-compartment PK model, with three compartments for the PD model and 10 structural PK-PD model parameters. 3. After the 5-FU treatment, platelet counts transiently decreased to a nadir level, showed a rebound to above the baseline level before recovering to baseline levels. Nadir platelet counts and rebounds varied with the AUC0-∞ level. The final PK-PD model effectively characterized platelet count data and final PD parameters were estimated with high certainty. 4. This PK-PD model and simulation may represent a valuable tool for quantifying and predicting the complete time-course of alterations in blood cell counts, and could contribute to the development of therapeutic strategies with 5-FU and assessments of various novel anticancer agents that are difficult to examine in humans.
Related Compounds
Related Articles:
TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.
2014-09-30
[Oncotarget 5(18) , 8107-22, (2014)]
cIEF for rapid pKa determination of small molecules: a proof of concept.
2014-10-15
[Eur. J. Pharm. Sci. 63 , 14-21, (2014)]
Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
2015-01-07
[World J. Gastroenterol. 21(1) , 164-76, (2015)]
[Iran. J. Pharm. Res. 14(2) , 395-405, (2015)]
2015-08-01
[Cancer Sci. 106 , 1000-7, (2015)]